Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05542134
Other study ID # KOIIM-UM
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 17, 2019
Est. completion date June 1, 2023

Study information

Verified date May 2023
Source University Medical Centre Ljubljana
Contact Marko Noc, MD, phD
Phone +38641723807
Email marko.noc@kclj.si
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

An observational study in which investigators will observe platelet inhibition in patients on VA ECMO acorrding to treatment with P2Y12 inhibitor.


Description:

Investigators will perform an observational study in which platelet inhibition in patients on VA ECMO acorrding to treatment with P2Y12 inhibitor will be observed. Participants will be divided into three groups: A: patients on V-A ECMO without P2Y12 inhibitors B patients on V-A ECMO with P2Y12 inhibitors with administration of P2Y12 inhibitor at the time of ECMO insertion C: patients on V-A ECMO already recieving P2Y12 inhibitors at the time of ECMO insertion. Blood samples will be taken prior to and at 2, 4, 12, 22, 48, 72 after ECMO insertion and after removal of an ECMO. VerifyNow System will be used to measure platelet agregation (PRU test).


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date June 1, 2023
Est. primary completion date June 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - all patients on VA ECMO Exclusion Criteria: - known P2Y12 alergy - thrombocitopenic patents (< 50*109/L), - patients treated with eptifibatide ali bivalirudin - patients younger than 18 years - pregnant patients

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
P2Y12 Platelet Aggregation Inhibitor
Verify now PRU test

Locations

Country Name City State
Slovenia UMC Ljubljana Ljubljana

Sponsors (1)

Lead Sponsor Collaborator
University Medical Centre Ljubljana

Country where clinical trial is conducted

Slovenia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Verify now P2Y12 platelet inhibition Platelet inhibition measured by VerifyNow as P2Y12 reaction units (PRU). Platelet reactivity reflects P2Y12 inhibitor effect with higher PRU values showing low P2Y12 response and lower values decreased platelet reactivity due to the effect of a P2Y12 inhibitor. (Time Frame: Hour 2 after VA ECMO insertion)
Primary Verify now P2Y12 platelet inhibition Platelet inhibition measured by VerifyNow as P2Y12 reaction units (PRU). Platelet reactivity reflects P2Y12 inhibitor effect with higher PRU values showing low P2Y12 response and lower values decreased platelet reactivity due to the effect of a P2Y12 inhibitor. (Time Frame: Hour 4 after VA ECMO insertion)
Primary Verify now P2Y12 platelet inhibition Platelet inhibition measured by VerifyNow as P2Y12 reaction units (PRU). Platelet reactivity reflects P2Y12 inhibitor effect with higher PRU values showing low P2Y12 response and lower values decreased platelet reactivity due to the effect of a P2Y12 inhibitor. (Time Frame: Hour 12 after VA ECMO insertion)
Primary Verify now P2Y12 platelet inhibition Platelet inhibition measured by VerifyNow as P2Y12 reaction units (PRU). Platelet reactivity reflects P2Y12 inhibitor effect with higher PRU values showing low P2Y12 response and lower values decreased platelet reactivity due to the effect of a P2Y12 inhibitor. (Time Frame: Hour 22 after VA ECMO insertion)
Primary Verify now P2Y12 platelet inhibition Platelet inhibition measured by VerifyNow as P2Y12 reaction units (PRU). Platelet reactivity reflects P2Y12 inhibitor effect with higher PRU values showing low P2Y12 response and lower values decreased platelet reactivity due to the effect of a P2Y12 inhibitor. (Time Frame: Hour 48 after VA ECMO insertion)
Primary Verify now P2Y12 platelet inhibition Platelet inhibition measured by VerifyNow as P2Y12 reaction units (PRU). Platelet reactivity reflects P2Y12 inhibitor effect with higher PRU values showing low P2Y12 response and lower values decreased platelet reactivity due to the effect of a P2Y12 inhibitor. (Time Frame: Hour 72 after VA ECMO insertion)
Primary Verify now P2Y12 platelet inhibition Platelet inhibition measured by VerifyNow as P2Y12 reaction units (PRU). Platelet reactivity reflects P2Y12 inhibitor effect with higher PRU values showing low P2Y12 response and lower values decreased platelet reactivity due to the effect of a P2Y12 inhibitor. (Time Frame: Hour 24 after VA ECMO removal)
See also
  Status Clinical Trial Phase
Recruiting NCT05284032 - A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001) Early Phase 1
Terminated NCT04631211 - Thrombosomes® in Bleeding Thrombocytopenic Patients Study Phase 2
Recruiting NCT03679858 - Platelet Antisedimentation Rate and Multiplate Exams in Patients on Antiplatelet Therapy and Controls
Completed NCT03408158 - HPA Antibodies and the Distribution of Antigen and Antibodies N/A
Recruiting NCT05091684 - Administration of Fibrinogen Concentrate for Refractory Bleeding Phase 2